Expert veterinary care for every stage of your pet’s life.
Emergency: 617-522-7282
Poison Control: 888-426-4435
Bringing pets and people together.
Advocate for animals, volunteer, or get help for your pet with our compassionate community services.
If your schedule looks anything like mine, you are seeing “doodles” — goldendoodles, Labradoodles, Bernedoodles, Aussiedoodles — and lots of them. Poodle crossbreeds have become some of the most popular dogs in the country, and with that surge comes something that we need to be talking more about: sebaceous adenitis (SA).
SA is a disease with a well-documented autosomal recessive mode of inheritance in standard poodles, and all of those poodle-mix dogs sitting in our lobbies carry that same genetic background. As of yet, we do not have published data about the prevalence of SA specifically in poodle crossbreeds, but the genetic logic is straightforward, and anecdotally, dermatologists and primary care veterinarians are seeing it.
Interestingly, SA has been diagnosed in more than 50 purebred dog breeds and their mixes, and it deserves some attention. For that reason, if you are working up a doodle, a poodle, an Akita, a Samoyed, a vizsla, or a Havanese with chronic, nonresponsive seborrhea, scaling that does not improve with routine therapy, or a coat that is just not right, SA should be on your differential list. Early recognition can make a meaningful difference in patient outcomes.
Sebaceous glands are adnexal structures associated with hair follicles. They produce sebum, the oily secretion that is critical for maintaining the skin’s epidermal lipid barrier, retaining moisture, and keeping the hair coat soft and supple. Without adequate sebum production, the skin becomes dry, hair becomes brittle, and the barrier function of the skin is compromised.
SA is an inflammatory skin disease in which the sebaceous glands are specifically targeted by an immune-mediated process, ultimately resulting in their progressive destruction. It was first described in the veterinary literature in the 1980s (Rosser et al., 1987) and has since been recognized in more than 50 dog breeds.
It is important to note that SA is classified as an immune-mediated disease, not an autoimmune disease. These terms are often used interchangeably in practice, but they are not the same thing. Autoimmune disease refers specifically to a condition in which the immune system generates an immune response against a defined self-antigen. In SA, we know that the immune system is driving the destruction of the sebaceous glands, and we can see the T-cell infiltrate targeting the gland on histopathology; however, a specific self-antigen has not been identified. The distinction matters clinically because it shapes how we talk to clients about the disease and how we think about treatment targets. We are managing a misdirected immune response, not necessarily an antibody-driven attack on a known self-protein. When you hear or read about SA described as “autoimmune,” understand that this is an oversimplification and that “immune-mediated” is the more accurate term.
The exact pathogenesis of SA remains incompletely understood, and this is a point worth communicating to your clients. Several theories have been proposed. One theory suggests that SA is driven by a cell-mediated immunologic reaction against one or more components of the sebaceous gland. Immunohistochemical examination of affected skin has demonstrated dendritic antigen-presenting cells and T-cells focused on the mid-follicular region and the sebaceous duct, which supports this immune-mediated theory (Rybnicek et al., 1998). The clinical response to cyclosporine further supports an immune-mediated mechanism.
An alternative theory proposes that a primary keratinization defect at the level of the sebaceous duct leads to ductal obstruction, with subsequent inflammatory destruction of the glands as a secondary event. This theory is supported by the observation that follicular keratosis (accumulation of keratin within the follicle) is a characteristic histopathologic feature of the disease, and that some patients respond to retinoids and vitamin A, which are therapies aimed at normalizing keratinization (Sousa, 2006).
A third theory involves abnormal lipid metabolism or storage, and is supported by the response to topical oil therapies and oral essential fatty acids (Pye, 2021).
In reality, multiple mechanisms likely contribute to SA, and the pathogenesis may well differ between breeds and individual dogs. What we can say is that the end result is the same: inflammation and eventual destruction of the sebaceous glands.
Affected dogs are generally young to middle-aged adults, with most presenting between one and five years of age. A male predisposition has been suggested in some studies, though a definitive sex predilection has not been firmly established (Tevell et al., 2008).
Breed predispositions are well-documented. An autosomal recessive mode of inheritance has been demonstrated in standard poodles and Akitas (Dunstan and Hargis, 1995; Reichler et al., 2001). Other breeds reported to be predisposed include Samoyeds, vizslas, Havanese, German Shepherds, English Springer Spaniels, Lhasa Apsos, chow chows, and Rottweilers (Pye, 2021; Frazer et al., 2011). That said, any breed can be affected, including mixed breeds.
One notable finding from the literature is that approximately 43% of dogs with SA had a concurrent chronic disease, such as hypothyroidism, at the time of diagnosis (Pye, 2021). This is clinically relevant because hypothyroidism can produce similar dermatologic signs, and both conditions may need to be addressed for optimal management.
The clinical presentation of SA varies depending on whether the dog has a long or short hair coat, and this distinction matters when you are examining patients.
In long-coated breeds (i.e., standard poodle, Akita, Samoyed, Havanese, and their crosses), the hallmark clinical sign is follicular casting. Follicular casts are keratinaceous material that envelops groups of hair shafts like a sleeve or cast on a limb. These casts remain attached to the hair as it grows and are quite distinct from other forms of seborrhea, and they should prompt you to think about SA. Early lesions often begin on the pinnae (particularly along the lateral margins), dorsal muzzle, forehead, and head. From there, lesions typically progress along the dorsum to involve the trunk, tail, and legs. Changes in hair color and texture may actually precede the development of overt scale and crusts. Hair may become lighter, darker, or straighter. In curly-coated breeds like poodles, this change in hair texture can be one of the earliest clues pointing to SA. As the disease progresses, the hair coat becomes dull and brittle, and hypotrichosis leading to frank alopecia develops. In the Akita, SA can present more severely, with generalized scaling and thickened skin. In English Springer Spaniels, a higher incidence of otitis externa has been reported compared to standard poodles and Akitas (Pye, 2021). In Havanese dogs, severe ulcerative pinnal lesions can develop, which is a particularly important recognition point for this breed (Frazer et al., 2011).
In short-coated breeds (i.e., vizsla, miniature pinscher, and dachshund), the clinical presentation tends to be milder, often described as a fine, white dandruff beginning on the head and ears that progressively spreads over the body. The scaling pattern may appear as round or S-shaped patches, producing what is classically described as a “moth-eaten” appearance to the coat. Some dogs may present with nodular lesions and plaques without the classical scaling and crusting. Secondary bacterial infections are less common in short-coated breeds.
Pruritus is not a primary feature of SA. When pruritus is present, it is almost always associated with secondary bacterial infection, which has been reported in approximately 40–42% of affected dogs (Tevell et al., 2008; Banovic, 2023). Owners may also report that their dog has developed an odor, which is attributable to the altered epidermal lipid layer and the presence of secondary infection.
This is where an Inflammation First™ approach matters. If you are seeing a dog with secondary infection, resist the urge to treat the infection in isolation. Secondary infection in the skin does not happen in a vacuum. It happens because something is driving it, whether that is allergic disease, an endocrinopathy, or in this case, the loss of sebaceous glands and the resulting compromise of the skin’s barrier. Treating infection without identifying and addressing the underlying cause leads to incomplete clearance, recurrence, and frustration for everyone involved. Always ask: Why is this dog infected?
When you are presented with a dog showing scaling, follicular casts, and alopecia, there are several differential diagnoses to consider and systematically rule out. These include superficial bacterial folliculitis, demodicosis (including Demodex injai in terrier breeds), dermatophytosis, primary idiopathic seborrhea, ichthyosis, follicular dysplasia, endocrinopathies (particularly hypothyroidism and hyperadrenocorticism), and leishmaniasis in endemic areas.
Performing basic diagnostics — such as skin scrapings, cytology, dermatophyte culture or PCR, and baseline bloodwork including a thyroid panel — before proceeding to biopsy is essential. Of all the in-house diagnostics available to you, trichography is the single most useful tool for raising your suspicion of SA. When you pluck hairs and examine them under the microscope, follicular casts will be visible as keratinous material adhered to the hair shafts. If you are seeing this on trichogram in combination with the right signalment and distribution, SA should move to the top of your list of potential diagnoses.
A diagnosis of SA can often be suspected, and in many cases strongly suspected, based on signalment, history, and clinical findings alone. In a classic presentation with follicular casts, the right breed, and a characteristic distribution, the clinical picture can be quite convincing. That said, skin biopsy remains the ideal and definitive diagnostic tool for SA. Biopsy confirms what you are seeing clinically, stages the disease, and provides critical prognostic information that will guide your treatment plan.
Multiple punch biopsies should be obtained from lesional skin at various stages of development. It helps to biopsy areas that represent both early and more advanced lesions, as this gives the pathologist the most complete picture.
Histopathologic findings vary depending on the stage of disease.
In early or active disease, nodular granulomatous to pyogranulomatous inflammation will be present at the level of the sebaceous gland. The cellular infiltrate is comprised of histiocytes, neutrophils, lymphocytes, and plasma cells. Intact or partially disrupted sebocytes may be visible within the granulomas. The defining finding is active inflammation specifically targeting the sebaceous glands.
In chronic or end-stage disease, the sebaceous glands may be completely absent, replaced by fibrosis, with minimal residual inflammation. Orthokeratotic hyperkeratosis with follicular plugging (follicular keratosis) is typically present. Acanthosis may also be noted.
I would encourage you to communicate to your pathologist that SA is on your differential list. The absence of sebaceous glands can be overlooked, if the pathologist is not specifically evaluating for this finding. A recent comparative histopathological study demonstrated that sebaceous glands were absent in 75% of biopsy specimens from Akitas and 62% from poodles diagnosed with SA (Puvača et al., 2026).
The biopsy also provides prognostic information. The presence of remaining sebaceous glands, even if inflamed, is a more favorable finding than their complete absence with fibrosis, as glands have the capacity to regenerate with appropriate treatment. Response to therapy largely depends on whether there are still living sebaceous glands present.
Before discussing specific therapies, we need to talk about setting appropriate expectations with your clients. SA is a chronic, controllable but non-curable disease. The goals of treatment are to control clinical signs, remove follicular casts and scale, improve hair coat quality, minimize ongoing inflammation to preserve remaining sebaceous glands, and manage secondary infections. Treatment is lifelong, and flares can occur even with consistent therapy. No single treatment is effective in all cases, and what works well for one patient may not work for another. Having this conversation upfront will improve client compliance and reduce frustration down the road.
Topical therapy is a cornerstone of SA management and should be part of every treatment plan, regardless of severity. In mild cases, topical therapy alone may be sufficient.
Antiseborrheic shampoos containing sulfur, salicylic acid, or zinc can be used to help remove scale and follicular casts. I recommend using these sparingly. These dogs already have compromised barrier function and reduced sebum production, and over-bathing with keratolytic shampoos can further dry the coat and skin. A soft brush can be used during bathing to gently help remove adherent scale and casts.
Oil soaks are, in my experience, where the real magic happens with SA. I call them “Spa Days” with my clients, and the name helps frame them as something positive rather than a chore. The purpose of an oil soak is to replace the epidermal lipids that the destroyed sebaceous glands can no longer produce, as well as restore some degree of normal barrier function. Baby oil, coconut oil, or a 1:1 dilution of mineral oil with water should be massaged into the coat and left in contact with the skin for one to six hours. The oil should then be removed through bathing with a degreasing shampoo or even dish soap, if needed. These soaks are typically recommended every one to four weeks, depending on the individual patient’s needs. While they may be labor-intensive, the clinical difference that they make is substantial, and in my practice, the dogs who do best with managing their SA are the ones whose owners commit to this part of the plan. One study found that topical therapy with oil soaks, humectants, and shampoos, when performed diligently, was as effective as cyclosporine treatment alone (Lortz et al., 2010). That finding is worth highlighting when cost is a limiting factor for the client.
Propylene glycol (50–75% dilution) can be applied as a spray or rinse after bathing. This acts as a humectant, aiding in moisture retention in the skin. It can also be used between baths, initially daily and then tapered to two to three times weekly for maintenance.
The reality is that topical therapy is labor-intensive, and compliance can be challenging for owners. Be honest with your clients about it, while also emphasizing that the more diligent the topical care is, the better the outcomes tend to be.
For moderate to severe cases, systemic therapy is typically necessary, in addition to topical management.
Cyclosporine modified is currently considered the most effective systemic treatment and is the best-studied option for SA. The standard dosage is 5 mg/kg administered orally once daily. Cyclosporine modified works by inhibiting calcineurin and preventing T-lymphocyte activation, thereby modulating the immune-mediated inflammatory attack on the sebaceous glands. In a study by Linek et al. (2005), 12 dogs treated with cyclosporine for 12 months showed significant improvement in clinical scores by four months, with continued improvement at eight and 12 months. Importantly, the percentage of hair follicles with sebaceous glands increased during treatment, suggesting that cyclosporine modified can promote regeneration of the glands. A multicentre, placebo-controlled trial by Lortz et al. (2010) confirmed that cyclosporine is effective, though the investigators noted that cyclosporine works best when combined with topical therapy.
Cyclosporine modified is not without its limitations. It can be expensive, and gastrointestinal side effects (i.e., vomiting and diarrhea) are relatively common. Routine monitoring with bloodwork is advised. At the immunomodulatory doses that we use in treating SA, cyclosporine modified is not truly immunosuppressive in the way that high-dose protocols are in transplant medicine, and significant opportunistic infections are uncommon at these doses. That said, monitoring remains good practice.
Oclacitinib (Apoquel) has more recently shown promise for the treatment of SA. While it was developed for itch relief in allergic dermatitis, oclacitinib’s mechanism of action (Janus kinase (JAK) inhibition that affects multiple proinflammatory cytokines) makes it relevant for immune-mediated diseases as well. A case report by Perez-Aranda et al. (2024) described a Rottweiler with SA who failed cyclosporine therapy but responded successfully to oclacitinib (0.7 mg/kg/day) combined with low-dose prednisolone. Controlled studies are still needed, but oclacitinib may be a useful treatment option in cyclosporine-refractory cases and may offer faster onset of clinical improvement. It is worth noting that oclacitinib is not the only JAK inhibitor now available in veterinary medicine. With the recent approvals of ilunocitinib (Zenrelia) and atinvicitinib (Numelvi), we may see additional case reports and data on JAK inhibitors in SA in the coming years. Be aware, however, that use of any JAK inhibitor for SA is off-label, and clinical decisions should be made with that context in mind.
Lokivetmab (Cytopoint) deserves a mention here as well. While it targets IL-31 and was developed for allergic itch, lokivetmab can be a useful adjunctive therapy for SA patients who are pruritic due to secondary infection or concurrent allergic disease. It will not address the underlying sebaceous gland pathology, or the inflammation, but it can improve comfort while you are getting the primary disease under control, and it is well-tolerated with a favorable safety profile.
Vitamin A has been used at high doses (10,000 IU administered orally once daily for dogs under 15 kg; 20,000 –30,000 IU daily for larger dogs) with variable results. In one retrospective study, approximately half of treated dogs showed improvement deemed “good” by their owners, but some patients worsened and others showed no response (White et al., 1995). Monitoring for hepatotoxicity is recommended with long-term use.
Synthetic retinoids (isotretinoin, etretinate) showed promise in older studies but are no longer available for veterinary patients. They are tightly regulated by the government, and access has essentially been eliminated. For this reason, retinoids are not a practical treatment option in current clinical practice.
Tetracycline/doxycycline and niacinamide have been anecdotally reported to provide benefit in some cases, based on their immunomodulatory (non-antibiotic) properties. Dogs under 25 kg typically receive 250 mg of each drug every eight hours, while dogs over 25 kg receive 500 mg. However, the current emphasis on antimicrobial stewardship is relevant here. The use of antibiotics for their immunomodulatory properties in inflammatory diseases is an area where we should exercise thoughtful restraint.
Glucocorticoids have generally been considered ineffective for SA and may even be counterproductive. Glucocorticoids can induce sebaceous gland atrophy, which is the opposite of what we need in a disease that is already destroying these glands (Banovic, 2023). While low-dose prednisolone has been used successfully in combination with oclacitinib in the case report discussed above, glucocorticoid monotherapy is not recommended.
Omega-3 and omega-6 fatty acids are almost always included as an adjunctive therapy. They support skin barrier function and may have mild anti-inflammatory properties. They are unlikely to be sufficient as sole therapy but complement other treatments well.
Secondary bacterial skin infections occur in a significant proportion of dogs with SA — between 40 and 42%, depending on the study — and recurrent infections are common because the loss of sebum impairs the normal skin barrier. When secondary infection is present, it should be identified through cytology and treated appropriately. Topical antimicrobial therapy (i.e., chlorhexidine shampoos, sprays, or wipes) is preferred as a first-line approach to reduce reliance on systemic antibiotics. If systemic antibiotics are necessary, an aerobic culture and susceptibility testing should guide your selection, particularly in recurrent or nonresponsive cases. This approach is consistent with current antimicrobial stewardship recommendations.
Because of the strong evidence of a genetic component to SA, affected dogs should not be bred. This is a conversation to have with your clients, particularly those with standard poodles and Akitas, as the autosomal recessive inheritance pattern has been established. Subclinically affected dogs — those with early histopathologic changes but without overt clinical signs — can produce affected puppies.
The Orthopedic Foundation for Animals (OFA) maintains a registry for SA in standard poodles. Dogs intended for breeding can be screened with annual skin biopsies, and results are registered to help track the heredity of the trait. Encouraging clients who are breeders to participate in this screening program is a proactive step.
The prognosis for SA depends on several factors, including the severity and extent of glandular loss at the time of diagnosis, the breed, and the individual patient’s response to therapy. Mild cases often respond well to topical management, and these patients may enjoy a good quality of life with relatively straightforward maintenance. More severe or advanced cases, particularly those with extensive dermal fibrosis and complete loss of sebaceous glands, carry a poorer prognosis for therapeutic response.
Marked improvement is typically seen within four months of initiating treatment, though clinical signs can wax and wane independently of therapy. Lifelong management and monitoring, including periodic reassessment and adjustment of the treatment plan, are the expectation.
Referral to a veterinary dermatologist is recommended when the clinical presentation is unclear, when the patient is not responding to initial treatment, when secondary infections are recurrent or severe, or when the client needs guidance on long-term management of a complex case. Getting a dermatologist involved early can help ensure that the diagnosis is confirmed appropriately and that a comprehensive treatment plan is initiated before significant glandular destruction occurs.
SA is a chronic, immune-mediated inflammatory disease targeting the sebaceous glands, leading to their progressive destruction. It is a condition that is often missed or mistaken for allergic disease, and early recognition is key. Think about SA when you see follicular casts, unexplained scaling, and alopecia, particularly in predisposed breeds and their crosses. Skin biopsy is required for definitive diagnosis, and the biopsy findings also inform prognosis. Treatment is multimodal, combining topical therapies with systemic options such as cyclosporine modified, and it requires lifelong commitment from the client. Setting clear expectations and maintaining open communication with your clients will go a long way in successfully managing this disease.
